Clesrovimab · Enflonsia

Monoclonal antibody

Also known as MK-1654

Approvedregulatory verdict

Evidence outlook

Approved: Respiratory Syncytial Virus Infection

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT04938830 · Merck Sharp & Dohme LLC
2021-11-30 – 2025-08-01 · RSV Infection
What this study did
Phase 2/3 (1)
Respiratory Syncytial Virus Infection
NCT04767373 · Merck Sharp & Dohme LLC
2021-04-07 – 2024-07-09 · Respiratory Syncytial Virus Infection
What this study did
Phase 2 (1)
Other / comorbidity
NCT04086472 · Merck Sharp & Dohme LLC
2019-10-28 – 2020-08-14 · Respiratory Syncytial Viruses
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03524118 · Merck Sharp & Dohme LLC
2018-09-20 – 2022-09-14 · Respiratory Tract Infection, Respiratory Syncytial Virus
What this study did
Phase 4 (1)
Other / comorbidity
NCT07824167 · Emory University
2026-11 – 2028-03 · RSV Infection
What this study did

Competitive landscape

This drug's own stage for Respiratory Syncytial Virus Infection: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Clesrovimab (Enflonsia): this drugApprovedMonoclonal antibodyRSV F proteinnot yet gradedNo reviewed efficacy summary in this indication
mRESVIAApprovedVaccineRSV pre-F proteinPartial signal
NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses).
EDP-323Phase 2Small moleculeRSV L proteinPartial signal
NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743)
ZelicapavirPhase 2Small moleculeRSV N protein (nucleoprotein)Weak signal
NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed
NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants
GSK5893818
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0256
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0291
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0340
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0341
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Enflonsia (Clesrovimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Phase 4RSV InfectionNot yet recruiting
Est. primary completion 2028-03 · NCT07824167 · CT.gov ↗
What to watch

See the full readout calendar ↗